PULM Stock Price & Charts Pulmatrix
Escrito por Radio Jerusalen el 10 diciembre 2020
Not all coins provided by Apex Crypto LLC are available to New York residents. Please visit /cryptocurrency to see a list of crypto available to trade. Our clearing firm Apex Clearing Corp has purchased an additional insurance policy. The coverage limits provide protection for securities and cash up to an aggregate of $150 million, subject to maximum limits of $37.5 million for any one customer’s securities and $900,000 for any one customer’s cash. Similar to SIPC protection, this additional insurance does not protect against a loss in the market value of securities. © 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.
Real-time analyst ratings, insider transactions, earnings data, and more. You can find your newly purchased Pulmatrix stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, and alternative assets. Discuss news and analysts’ What Is Bollinger Band? price predictions with the investor community. No content on the Webull Financial LLC website shall be considered as a recommendation or solicitation for the purchase or sale of securities, options, or other investment products.
WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data. Pulmatrix stock was originally listed at a price of $3,625.00 in Mar 21, 2014. If you had invested in Pulmatrix stock at $3,625.00, your return over the last 8 years would have been -99.89%, for an annualized return of -57.55% . Overall, this stock passed 10/33 due dilligence checks and has average fundamentals, according to our automated analysis. When you see Pulmatrix stock appear in the results, tap it to open up the purchase screen. Sign Up NowGet this delivered to your inbox, and more info about our products and services.
Provide specific products and services to you, such as portfolio management or data aggregation. WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. All investments involve the risk of loss and the past performance of a security OctaFX Forex Broker Review or a financial product does not guarantee future results or returns. What analysts recommend for PULM stock, on a scale from 1 to 5. Securities trading is offered to self-directed customers by Webull Financial LLC, a broker dealer registered with the Securities and Exchange Commission .
Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as «gurus» may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein.
News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services. All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.
Pulmatrix, Inc. is a biopharmaceutical company which is engaged in developing inhaled therapies for serious pulmonary disease. The Company’s proprietary product pipeline includes PUR1900, an inhaled anti-fungal for cystic fibrosis, PUR0200, a branded generic for chronic obstructive pulmonary disease… Market cap is the total market value of a publicly traded company’s outstanding shares. Money Flow Uptick/Downtick RatioMoney flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an «uptick» in price and the value of trades made on a «downtick» in price.
An explanatory brochure is available upon request or at Our clearing firm, Apex Clearing Corp., has purchased an additional insurance policy.. These 5 stocks under $10 could ignite soonHere’s a technical look at how to trade several under-$10 stocks triggering breakout trades. These 5 stocks under-$10 could light up soonHere’s a technical look at how to trade several under $10 stocks that could trigger big breakout trades soon. One share of PULM stock can currently be purchased for approximately $3.82. The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 4th 2023. In the past three months, Pulmatrix insiders have not sold or bought any company stock.
The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov, and Robert S. Langer, Jr. Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which…
About Pulmatrix (NASDAQ:PULM) Stock
Please read the Characteristics and Risks of Standardized Options before trading options. All investments involve risk, and not all risks are suitable for every investor. The value of securities may fluctuate and as a result, clients may lose more than their What to Expect From Pepperstone Review original investment. The past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss in a down market.
- See how Bullish or Bearish a stock is based on its recent media coverage.
- Pulmatrix’s market cap is calculated by multiplying PULM’s current stock price of $3.82 by PULM’s total outstanding shares of 3,639,185.
- The Company’s proprietary product pipeline includes PUR1900, an inhaled anti-fungal for cystic fibrosis, PUR0200, a branded generic for chronic obstructive pulmonary disease which are in different clinical stage.
- The value of securities may fluctuate and as a result, clients may lose more than their original investment.
The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. In addition, the Company focuses on pulmonary diseases through collaboration with partners, including PUR0200, a generic in clinical development for chronic obstructive pulmonary disease. Looking for continuation and possible breakout today in PULM Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs.
Dalmore and Apex Crypto, LLC are not affiliated with any of the Public Holdings subsidiaries. Commission-free trading of stocks and ETFs refers to $0 commissions for Open to the Public Investing self-directed individual cash brokerage accounts that trade the U.S.-listed, registered securities electronically during the Regular Trading Hours. Keep in mind that other fees such as regulatory fees, Premium subscription fees, commissions on trades during extended trading hours, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more.
Since then, PULM shares have decreased by 56.4% and is now trading at $3.82. The company’s average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings. Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes.
Pulmatrix – PULM Stock Forecast, Price & News
Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. For example, a price above its moving average is generally considered an upward trend or a buy.
The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades. Net money flow is the value of uptick trades minus the value of downtick trades. Shares Sold ShortThe total number of shares of a security that have been sold short and not yet repurchased.Change from LastPercentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month.Percent of FloatTotal short positions relative to the number of shares available to trade. Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market.
Market capitalization is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Pulmatrix saw a drop in short interest in the month of October. As of October 31st, there was short interest totaling 52,500 shares, a drop of 19.8% from the October 15th total of 65,500 shares. Based on an average trading volume of 94,400 shares, the days-to-cover ratio is currently 0.6 days. 1 Wall Street analysts have issued «buy,» «hold,» and «sell» ratings for Pulmatrix in the last twelve months. The consensus among Wall Street analysts is that investors should «buy» PULM shares.
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.